A joint action between five Portuguese research institutions – IGC, iMM, iBET, CEDOC-NMS, ITQB-NOVA – Serology4COVID consortium – is developing a new serological test for COVID-19. The implementation of a scalable and economical serological test is essential to understand the expansion of immunity in the population and to support the implementation of new strategies to control the spread and/or minimize its consequences for health, society and the economy.

IGC iMM CEDOC NMS

 

SARS-CoV-2 antibody testing for NOVA University Lisbon academic community

NOVA University of Lisbon carried out a screening of COVID-19 in its community, by conducting serological tests for the presence of anti-SARS-CoV-2 antibodies, to teachers, researchers, employees and students who attend face-to-face classes and all those who live in the university’s residences, in order to guarantee the best health and safety conditions, considering the current and the next academic year. These serological tests were developed by CEDOC, within the scope of the Serology4COVID Consortium.

More than 1640 serological tests have been performed in 12 days, during the month of July.

More information CEDOC

 

The Champalimaud Foundation, in collaboration with the Order of Nurses, has started a study with serological tests that aims to assess the existence of antibodies to SARS-Cov-2 in about 600 health professionals (nurses and operational assistants) in two major hospitals that are very active in the treatment of COVID-19 patients – Hospital de Santo António, in Porto, and Hospital de Santa Maria, in Lisbon.

Champalimaud Foundation

 

Other Collaborative Efforts